Navigation path

Pharmaceuticals - Community Register

  

List of referrals for human medicinal products

Goserelin cell pharm 3,6 mg Implantat and associated names

Product name: Goserelin cell pharm 3,6 mg Implantat and associated names
Also marketed in the EU under the name(s): Novgos, Novogos
Active substance: goserelin
Indication: Advanced prostate cancer where an endocrine treatment is indicated.
Marketing Authorisation Holder: Not applicable

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
20/09/2011 Referral EMEA/H/A-36/1297 (2011)6598 of 16/09/2011